Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia

Haematologica

Volumn 89, Issue 8, 2004, Pages 998-1008

  Ferrara, Felicetto ^a,b   Palmieri, Salvatore ^a   Mele, Giuseppina ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Acute myeloid leukemia; Prognostic factors; Relapse; Therapeutic options

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BCL 2 INHIBITOR; CALICHEAMICIN; CEP 701; CLOFARABINE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; MIDOSTAURIN; MITOXANTRONE; NUCLEOSIDE ANALOG; OBLIMERSEN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; RETINOIC ACID; SEMAXANIB; SU 5614; SUNITINIB; TIPIFARNIB; TROXACITABINE; UNCLASSIFIED DRUG; VALPROIC ACID; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CYTOGENETICS; FATIGUE; HUMAN; HYPOKALEMIA; LEUKEMIA REMISSION; LIVER TOXICITY; PROGNOSIS; SIDE EFFECT; STEM CELL TRANSPLANTATION; TREATMENT INDICATION; VEIN OCCLUSION;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, MYELOID; PROGNOSIS; RECURRENCE;

EID: 3943062139     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (120)

1. Schiffer CA. Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia. New Engl J Med 2003;349:727-9.
2. Kohlmann A, Schoch C, Schnittger S, Dugas M, Hiddemann W, Kern W, et al. Molecular characterization of acute leukemias by use of microarray technology. Genes Chromosomes Cancer 2003;37:396-405.
3. Ravandi F, Talpaz M, Estrov Z. Modulation of cellular signalling pathways: prospects for targeted therapy in haematological malignancies. Clin Cancer Res 2003;9:535-50.
4. Stirewalt DL, Meshinchi S, Radich JP. Molecular targets in acute myelogenous leukemia. Blood Rev 2003;17:15-23.
5. Pinto A, Zagonel V, Ferrara F. Acute myeloid leukaemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol 2001;39:275-87.
6. Ferrara F, Mirto S, Zagonel V, Pinto A. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. Leuk Lymphoma 1998;29:375-82.
7. Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000;14:476-9.
8. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 2002;43:1715-27.
9. Stanisic S, Kalaycio M. Treatment of refractory and relapsed acute myelogenous leukemia. Expert Rev Anticancer Ther 2002;2:287-95.
10. Robak T, Wrzesien K. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma 2002;43:281-91.
11. Newland A. Progress in the treatment of acute myeloid leukaemia in adults. Int J Hematol 2002;76 Suppl 1:253-8.
12. Stone RM. Treatment of acute myeloid leukemia: state-of-the-art and future directions. Semin Hematol 2002;39 Suppl 2:4-10.
13. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-9.
14. Ginsberg JP, Orudjev E, Bunin N, Felix CA, Lange BJ. Isolated extramedullary relapse in acute myeloid leukemia: a retrospective analysis. Med Pediatr Oncol 2002;38:387-90.
15. Lee KH, Lee JH, Choi SJ, Lee JH, Kim S, Seol M, et al. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant 2003;32:835-42.
16. Ferrara F, Del Vecchio L. Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity. Haematologica 2002;87:306-19.
17. Wiernik PH, De Bellis R, Muxi P, Dutcher JP. Extramedullary acute promyelocytic leukemia. Cancer 1996;78:2510-4.
18. Evans GD, Grimwade DJ. Extramedullary disease in acute promyelocytic leukemia. Leuk Lymphoma 1999;33:219-29.
19. Specchia G, Lo Coco F, Vignetti M, Awisati G, Fazi P, Albano F, et al. Extra-medullary involvement at relapse in acute promyelocytic leukemia patients treated or not with ATRA. A report by the GIMEMA group. J Clin Oncol 2001;19:4023-8.
20. Breccia M, Carmosino I, Diverio D, De Santis S, De Propris MS, Romano A, et al. Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. Br J Haematol 2003;120:266-70.
21. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002;16:1959-73.
22. Grinwade D. The significance of minimal residual disease in patients with t(15;17). Best Pract Res Clin Haematol 2002;15:137-58.
23. Mandelli F, Diverio D, Awisati G, Luciano A, Barbui T, Bernasconi C, et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997;90:1014-21.
24. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999;94:12-6.
25. Tallman M, Nabhan C. Management of acute promyelocytic leukemia. Curr Oncol Rep 2002;4:381-9.
26. Marcucci G, Caligiuri MA, Bloomfield CD. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically? Eur J Haematol 2003;71:143-54.
27. Buonamici S, Ottavini E, Testoni N, Montefusco V, Visani G, Bonifazi F, et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002;99:443-9.
28. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003;102:2746-55.
29. Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W, et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol 2003;23:4413-22.
30. Morschhauser F, Cayuela JM, Martini S, Baruchel A, Rousselot P, Socie G, et al. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. J Clin Oncol 2000;18:788-94.
31. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002;16:2115-21.
32. Garg M, Moore H, Tobal K, Liu Yin JA. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 2003;123:49-59.
33. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003;101:1698-704.
34. Löwenberg B. Prognostic factors in acute myeloid leukemia. Best Pract Res Clin Haematol 2001;14:65-75.
35. Kern W, Haferlach T, Schoch C, Loftier H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AML-CG) 1992 Trial. Blood 2003;101:64-70.
36. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-33.
37. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000;96:4075-83.
38. Kern W, Schoch C, Haferlach T, Unterhalt M, Wormann B, Buchner T, et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 2000;14:226-31.
39. Kern W, Schoch C, Schnittger S, Ludwig WD, Hiddemann W, Schoch C. Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy. Leukemia 2002;14:2084-91.
40. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Buchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 1990;4:184-8.
41. Davis CL, Rohatiner AZ, Lim J, Whelan JS, Oza AM, Amess J, et al. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period. Br J Haematol 1993;83:404-11.
42. Thalhammer F, Geissler K, Jager U, Kyrle PA, Pabinger I, Mitterbauer M, et al. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol 1996;72:216-22.
43. Weltermann A, Fonatsch C, OA Haas, Greinix HT, Kahls P, Mitterbauer G, et al. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia 2004;12:293-302.
44. Ferrara F, Morabito F, Latagliata R, Martino B, Annunziata M, Oliva E, et al. Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukaemia relapsing after first complete remission Haematologica 2001;86:814-20.
45. Vignetti M, Orsini E, Petti MC, Moleti ML, Andrizzi C, Pinto RM, et al. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single-centre experience. Ann Oncol 1996;7:933-8.
46. Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, et al. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia 1993;7:196-9.
47. De Witte T, Suciu S, Selleslag D, Labar B, Roozendaal K, Zittoun R, et al. Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group. Ann Hematol 1996;72:119-24.
48. Karanes C, Kopecky KJ, Head DR, Grever MR, Hymed HE, Kraut EH, et al. A phase III comparison of high dose ARAC (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. Leuk Res 1999;23:787-94.
49. Martino R, Guardia R, Altes A, Sureda A, Brunei S, Sierra J. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II GEMIA protocol. Haematologica 1999;84:226-30.
50. Virchis A, Koh M, Rankin P, Mehta A, Potter M, Hoffbrand AV, et al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes, Br J Haematol 2004;124:26-32.
51. Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 1998;58:105-9.
52. Ferrara F, Leoni F, Pinto A, Mirto S, Morra E, Zagonel V, et al. Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. Cancer 1999;86:2006-13.
53. Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 1996;81:513-20.
54. Jackson G, Taylor P, Smith GM, Marcus R, Smith A, Chu P, et al. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess blasts in transformation. Br J Haematol 2001;112:127-37.
55. Neufang A, Franklin J, Tesch H, Diehl V, Dias WP. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol 1999;78:418-25.
56. Ferrara F, Melillo L, Montillo M, Leoni F, Pinto A, Mele G, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation. Ann Hematol 1999;78:380-4.
57. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993;11:116-24.
58. Tafuri A, Andreeff M. Kinetic rationale for cytokine induced recruitment of myeloblastic leukemia followed by cycle specific chemotherapy in vitro. Leukemia 2000;4:826-34.
59. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colonystimulating factor. J Clin Oncol 2004;12:671-8.
60. Camera A, Palmieri S, Cantore N, Mele G, Rinaldi CR, Villa MR, et al. Fludarabine and cytarabine as continuous sequential infusion plus liposomal daunorubicin (Daunoxome) as salvage therapy for refractory or relapsed patients with acute myeloid leukemia. Haematologica 2003;88 Suppl 15:84-5.
61. Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, et al. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica 2002;87:52-8.
62. Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ, et al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant 2002;8:435-43.
63. Aversa F, Velardi A, Tabilio A, Reisner Y, Martelli MF. Haploidentical stem cell transplantation in leukemia. Blood Rev 2001;15:111-9.
64. Massenkeil G, Nagy M, Lawang M, Rosen O, Genvresse I, Geserick G, et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant 2003;31:339-45.
65. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003;102:3052-9.
66. Taussig DC, Davies AJ, Cavenagh JD, Oakervee H, Syndercombe-Court D, Kelsey S, et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol 2003;15:3060-5.
67. Imoto S, Murayama T, Gomyo H, Mizuno I, Sugimoto T, Nakagawa T, et al. Long-term molecular remission induced by donor lymphocyte infusions for recurrent acute myeloblastic leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000;26:809-10.
68. Wasch R, Bertz H, Kunzmann R, Finke J. Incidence of mixed chimaerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic stem cell transplantation. Br J Haematol 2000;109:743-50.
69. Linker CA. Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant 2003;31:731-8.
70. Gorin NC. Autologous stem cell transplantation for adult acute leukemia Curr Opin Oncol 2002;14:152-9.
71. Meloni G, De Fabritiis P, Petti MC, Mandelli F. BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. Blood 1990;75:2282-5.
72. Meloni G, Vignetti M, Awisati G, Capria S, Micozzi A, Giona F, et al. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Bone Marrow Transplant 1996;18:693-8.
73. Smith BD, Jones RJ, Lee SM, Piantadosi S, Vala MS, Fuller D. Autologous bone marrow transplantation with 4-hydroperoxy-cyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience. Br J Haematol 2002;117:907-13.
74. Lioure B, Witz F, Deconninck E. Autologous stem cell transplantation (ASCT) represents the best consolidation therapy for acute myelogenous leukemia (AML) in second complete remission (CR): a retrospective study of the GOE-LAMS group. Blood 1997;90 Suppl 1:384a [abstract].
75. Linker C, George S, Hurd D, Ries C, Negrin R, Blume K, et al. Autologous stem cell transplantation for acute myeloid leukemia in second remission-CALGB 9620. Blood 2001;98 Suppl 1:689a[abstract].
76. Giles FJ. New drugs in acute myeloid leukemia. Curr Oncol Rep 2002;4:369-74.
77. Stone RM. New therapies in leukemia: renewed hope. J Hematother Stem Cell Res 2002;11:583-7.
78. Ravandi F, Kantarjian H, Giles F, Cortes J. New agents in acute myeloid leukemia and other myeloid disorders. Cancer 2004:100:441-54.
79. Tomblyn MR, Tallman MS. New developments in antibody therapy for acute myeloid leukemia. Semin Oncol 2003;30:502-8.
80. Scheinberg DA, Tanimoto M, McKenzie S, Strife A, Old LJ, Clarkson BD. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia 1989;3:440-5.
81. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA. Molecular remission induction with retinoic acid and anti-mCD33 monoclonal antibody HuM 195 in acute promyelocytic leukemia. Clin Cancer Res 2000;6:372-80.
82. Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 2003;17:314-8.
83. Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, et al. Use of gemtuzumab ozogamicin (Mylotarg) in 157 patients 60 years of age with acute myeloid leukemia in first relapse. Blood 2003;102:176a.
84. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002;99:2310-4.
85. Erba HP, Stadtmauer EA, Larson RA et al. Risk Assessment for hepatic venoocclusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg) with or without hematopoietic stem cell transplantation. Blood 2003;102:871a[abstract].
86. Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A, et al. A feasibility study of simultanenous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003;102:4277-83.
87. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, et al Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2003;27:893-7.
88. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 2003;51:87-90.
89. Karp JE. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Semin Hematol 2001;38 Suppl 7:16-23.
90. Lancet JE, Karp JE. Farnesyl transferase inhibitors in myeloid malignancies. Blood Rev 2003;17:123-9.
91. Harousseau J, Reiffers J, Lowenberg B, Thomas X, Huguet F, Fenaux P, et al. Zarnestra (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML): results of a multicenter phase 2 Study. Blood 2003;176a [abstract].
92. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167-73.
93. Kantarjian HM, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, et al. Phase II clinical and pharmacology study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379-86.
94. Faderl S, Gandhi V, Garcia-Manero G, Thomas DA, Cortes JE, O Brien S, et al. Clofarabine is active in combination with cytarabine (ara-C) in adult patients (pts) in first relapsed and primary refractory acute leukemia and high-risk myelodys-plastic syndrome (MDS). Blood 2003;102:615a[abstract].
95. Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL, et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol 2001;19:762-71.
96. Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 2002;20:656-64.
97. Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, et al. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol 2003;21:1050-6.
98. Löwenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2003;82-101.
99. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003;3:650-65.
100. Sheikhha MH, Awan A, Tobal K, Liu Yin JA. Prognostic significance of FLT3 ITD and D835 mutations in AML patients. Hematol J 2003;4:41-6.
101. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-53.
102. Del Poeta G, Del Principe MI, Buccisano F, Venditti A, Maurillo L, Tamburini A, et al. Clinical significance of spontaneous apoptosis is independent from immaturity in acute myeloid leukemia (AML). Blood 2003;102:100a[abstract].
103. Cotter FE. Antisense therapy of hematologic malignancies. Semin Hematol 1999;36:9-14.
104. Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003;101:425-32.
105. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000;247:521-34.
106. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D. Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer 1990;45:263-8.
107. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004;22:1078-86.
108. Issa JPJ, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 1997;11 Suppl 1:57-511.
109. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001;134:573-86.
110. Christman JK. E and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-95.
111. Issa JPJ, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-40.
112. Pandolfi PP, Moe-Behrenz GHG. Targeting aberrant transcriptional repression in acute myeloid leukemia. Rev Clin Exp Hematol 2003;7:139-59.
113. Estey EH. Treatment options for relapsed acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003;16:521-34.
114. Leoni F, Gianfaldoni G, Annunziata M, Fanci R, Ciolli S, Nozzoli C, et al. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. Haematologica 2002;87:485-9.
115. Shen Y, Shen ZX, Van H, Chen J, Zeng XY, Li JM, et al. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia. 2001;15:735-41.
116. Petti MC, Pinazzi MB, Diverio D, Romano A, Petrucci MT, De Santis S, et al. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). Br J Haematol 2001;115:63-5.
117. Sanz MA, de la Rubia J, Bonanad S, Barragan E, Sempere A, Martin G, et al. Prolonged molecular remission after PML/RARα-positive autologus peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pre-transplant minimal residual disease in the graft? Leukemia 1998;12:992-5.
118. Ruiz-Arguelles G, Garces-Eisele J, Ruiz-Arguelles A. Continued complete remission after a PML/RAR-α+ autograft in acute promyelocytic leukemia. Eur J Haematol 1996;55:186-7.
119. Ferrara F, Palmieri S, Annunziata M, Pocali B, Viola A, Pane F. Prolonged molecular remission after autologous stem cell transplantation in relapsed acute promyelocytic leukemia: report on six patients autografted in molecular remission by molecularly negative graft. Haematologica 2004;89:621-2.
120. Estey EH. Thall PF. New designs for phase 2 clinical trials. Blood 2003;102:442-8.